Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where V. C. C. Cheng is active.

Publication


Featured researches published by V. C. C. Cheng.


The Lancet | 2003

Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study

J. S. M. Peiris; Chung-Ming Chu; V. C. C. Cheng; K. S. Chan; Ivan Fan-Ngai Hung; L. L. M. Poon; Kin-Ip Law; Bone Siu-Fai Tang; T. Y. W. Hon; Chan Cs; Kh Chan; J. S. C. Ng; Bo-Jian Zheng; W.L. Ng; Raymond W. M. Lai; Yi Guan; Kwok-Yung Yuen

n Summaryn n Backgroundn We investigated the temporal progression of the clinical, radiological, and virological changes in a community outbreak of severe acute respiratory syndrome (SARS).n n n Methodsn We followed up 75 patients for 3 weeks managed with a standard treatment protocol of ribavirin and corticosteroids, and assessed the pattern of clinical disease, viral load, risk factors for poor clinical outcome, and the usefulness of virological diagnostic methods.n n n Findingsn Fever and pneumonia initially improved but 64 (85%) patients developed recurrent fever after a mean of 8.9 (SD 3.1) days, 55 (73%) had watery diarrhoea after 7.5 (2.3) days, 60 (80%) had radiological worsening after 7.4 (2.2) days, and respiratory symptoms worsened in 34 (45%) after 8.6 (3.0) days. In 34 (45%) patients, improvement of initial pulmonary lesions was associated with appearance of new radiological lesions at other sites. Nine (12%) patients developed spontaneous pneumomediastinum and 15 (20%) developed acute respiratory distress syndrome (ARDS) in week 3. Quantitative reverse-transcriptase (RT) PCR of nasopharyngeal aspirates in 14 patients (four with ARDS) showed peak viral load at day 10, and at day 15 a load lower than at admission. Age and chronic hepatitis B virus infection treated with lamivudine were independent significant risk factors for progression to ARDS (p=0.001). SARS-associated coronavirus in faeces was seen on RT-PCR in 65 (97%) of 67 patients at day 14. The mean time to seroconversion was 20 days.n n n Interpretationn The consistent clinical progression, shifting radiological infiltrates, and an inverted V viral-load profile suggest that worsening in week 2 is unrelated to uncontrolled viral replication but may be related to immunopathological damage.n Published online May 9, 2003 http://image.thelancet.com/extras/03art4432web.pdfn n


European Journal of Clinical Microbiology & Infectious Diseases | 2002

Clinical Spectrum of Paradoxical Deterioration During Antituberculosis Therapy in Non-HIV-Infected Patients

V. C. C. Cheng; Pak-Leung Ho; Rodney A. Lee; K. S. Chan; Kk Chan; Pcy Woo; S. K. P. Lau; Kwok-Yung Yuen

Abstract.Paradoxical deterioration during antituberculosis therapy, defined as the clinical or radiological worsening of pre-existing tuberculous lesions or the development of new lesions in a patient who initially improves, remains a diagnostic dilemma. Although different clinical presentations of paradoxical response have been described, a systematic analysis of the entity in non-HIV-infected patients is lacking. Reported here are two cases of paradoxical deterioration in which sequential changes in lymphocyte counts and tuberculin skin test results are emphasized. In addition, 120 episodes of paradoxical response after antituberculosis treatment were reviewed. Of the total 122 episodes, 101 (82.8%) were associated with extrapulmonary tuberculosis. The median time from commencement of treatment to paradoxical deterioration was 60 days. The median time to onset of central nervous system manifestations (63 days) was longer than the time to onset of manifestations at other sites (56 days) (P=0.02). Development of new lesions in anatomical sites other than those observed at initial presentation was observed in 31 (25.4%) episodes. A surge in the lymphocyte count, accompanied by an exaggerated tuberculin skin reaction, was observed in our patients during the paradoxical deterioration, analogous to the findings in HIV-positive patients. Treatment of the paradoxical response included surgical intervention (60.7%) and administration of steroids (39.3%). The use of steroids appeared to be safe in this series, as 95% of the Mycobacterium tuberculosis isolates were susceptible to first-line antituberculosis therapy.


Thorax | 2004

Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings

Chung-Ming Chu; V. C. C. Cheng; I. F. N. Hung; M.M.L. Wong; Kh Chan; K. S. Chan; Richard Y. T. Kao; L. L. M. Poon; C L P Wong; Yi Guan; J. S. M. Peiris; Kwok-Yung Yuen

Background: The clinical response of patients with severe acute respiratory syndrome (SARS) to a combination of lopinavir/ritonavir and ribavirin was examined after establishing the in vitro antiviral susceptibility of the SARS associated coronavirus to a panel of antiviral agents. Methods: The in vitro susceptibility of the prototype of SARS associated coronavirus to a panel of nucleoside analogues and protease inhibitors currently licensed for clinical use was studied. Forty one patients with SARS followed for 3 weeks were treated with a combination of lopinavir/ritonavir and ribavirin. The clinical progress and virological outcomes were monitored and compared with 111 patients treated with ribavirin only who served as historical controls. Results: In vitro antiviral activity against SARS associated coronavirus was demonstrated for lopinavir and ribavirin at concentrations of 4 µg/ml and 50 µg/ml, respectively, only at 48 hours. The adverse clinical outcome (ARDS or death) was significantly lower in the treatment group than in the historical controls (2.4% v 28.8%, p<0.001) at day 21 after the onset of symptoms. The adverse outcome remained significantly lower in the treatment group than in the controls—both those diagnosed early (p<0.001) and those diagnosed later in the course of the epidemic (pu200a=u200a0.002)—but there was no significant difference in adverse outcome rates between the two time periods (pu200a=u200a0.548). No time related difference in outcome was observed in the control groups. A reduction in steroid usage and nosocomial infections was seen in patients initially treated with lopinavir/ritonavir, and these patients had a decreasing viral load and rising peripheral lymphocyte count. Multivariate analysis showed that age, hepatitis B carrier status, and lack of treatment with this antiviral combination were independent predictors of an adverse outcome. Lopinavir/ritonavir treatment was associated with a better outcome even when adjusted for baseline lactate dehydrogenase level. Conclusions: The apparent favourable clinical response with lopinavir/ritonavir and ribavirin supports further randomised placebo controlled trials in patients with SARS.


European Journal of Clinical Microbiology & Infectious Diseases | 2003

Risk factors for development of paradoxical response during antituberculosis therapy in HIV-negative patients.

V. C. C. Cheng; Wing-Cheong Yam; Pcy Woo; S. K. P. Lau; Ivan Fan-Ngai Hung; S. P. Y. Wong; W.C. Cheung; Kwok-Yung Yuen

The risk factors for development of paradoxical response were studied in a cohort of 104 patients with culture-documented Mycobacterium tuberculosis infection. Paradoxical deterioration occurred in 16 (15.4%) patients (case group) during antituberculosis therapy, involving lungs and pleura (n=4), spine and paraspinal tissue (n=5), intracranium (n=3), peritoneum (n=2), bone and joint (n=1), and lymph node (n=1). The median time from commencement of treatment to paradoxical deterioration was 56 days (range, 20–109 days). Compared with 53 patients without clinical deterioration after antituberculosis therapy (control group), patients with paradoxical response were more likely to have extrapulmonary involvement (62.5% vs. 17.0%; P<0.05) at initial diagnosis, to have lower baseline lymphocyte counts (672±315xa0cells/μl vs. 1,328±467xa0cells/μl; P<0.001), and to exhibit a greater surge in lymphocyte counts (627±465xa0cells/μl vs. 225±216 cells/μl; P<0.05) during paradoxical response. Further studies on lymphocyte subsets and cytokine levels would be useful in understanding the exact immunological mechanisms involved in immunorestitution.


Journal of Clinical Pathology | 2004

Clinical evaluation of the polymerase chain reaction for the rapid diagnosis of tuberculosis

V. C. C. Cheng; Wing-Cheong Yam; I. F. N. Hung; Pcy Woo; S. K. P. Lau; Bone Siu-Fai Tang; Kwok-Yung Yuen

Aims: Use of the polymerase chain reaction for the detection of Mycobacterium tuberculosis (TB PCR) as a basis for making clinical decisions on the initiation of antituberculosis treatment was studied. Methods: A retrospective study involving a cohort of 155 patients being investigated for tuberculosis in an infectious disease consultation service was undertaken. TB PCR was performed on pulmonary and extrapulmonary specimens from these patients. The sensitivity of TB PCR was analysed. Results: Of the 155 patients, 144 fitted the clinical diagnosis of tuberculosis, and 112 of them were culture positive for M tuberculosis. Sixty (58.3%) patients with clinical features suggestive of tuberculosis received antituberculosis treatment based on positive TB PCR alone. Of 224 clinical specimens (138 pulmonary and 86 extrapulmonary) sent for TB PCR, 148 (99 pulmonary and 49 extrapulmonary) were positive in 117 patients. Of the 690 clinical specimens sent for culture, 279 were positive for M tuberculosis in 112 patients. The diagnostic sensitivity of TB PCR was 75.9% (85 of 112) and 81.3% (117 of 144) in patients with culture confirmed and clinically diagnosed tuberculosis, respectively. Using culture as the gold standard, the overall sensitivity of TB PCR was 78.3%, and for pulmonary and extrapulmonary specimens it was 82.3% and 72.0%, respectively. Conclusions: TB PCR is a rapid and reliable test in the diagnosis and management of tuberculosis.


Emerging Infectious Diseases | 2004

Viral loads in clinical specimens and SARS manifestations.

Ivan Fan-Ngai Hung; V. C. C. Cheng; Ayy Wu; Bone Siu-Fai Tang; Kh Chan; Chung-Ming Chu; M.M.L. Wong; Wai-ting Hui; L. L. M. Poon; Doris M.W. Tse; K. S. Chan; Patrick C. Y. Woo; S. K. P. Lau; J. S. M. Peiris; Kwok-Yung Yuen

The number of anatomical sites with detectable viral loads by RT-qPCR appeared to correlate with death risk.


Journal of Clinical Virology | 2004

In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds.

Fe Chen; Kh Chan; Y Jiang; Richard Y. T. Kao; H.T Lu; K.W Fan; V. C. C. Cheng; Wayne H.W. Tsui; Ivan Fan-Ngai Hung; Terri S.W. Lee; Yi Guan; J. S. M. Peiris; Kwok-Yung Yuen

n Abstractn n Effective antiviral agents are urgently needed to combat the possible return of severe acute respiratory syndrome (SARS). Commercial antiviral agents and pure chemical compounds extracted from traditional Chinese medicinal herbs were screened against 10 clinical isolates of SARS coronavirus by neutralisation tests with confirmation by plaque reduction assays. Interferon-beta-1a, leukocytic interferon-alpha, ribavirin, lopinavir, rimantadine, baicalin and glycyrrhizin showed antiviral activity. The two interferons were only active if the cell lines were pre-incubated with the drugs 16h before viral inoculation. Results were confirmed by plaque reduction assays. Antiviral activity varied with the use of different cell lines. Checkerboard assays for synergy were performed showing combinations of interferon beta-1a or leukocytic interferon-alpha with ribavirin are synergistic. Since the clinical and toxicity profiles of these agents are well known, they should be considered either singly or in combination for prophylaxis or treatment of SARS in randomised placebo controlled trials in future epidemics.n n


Bone Marrow Transplantation | 2002

Clinicopathological features and risk factors of clinically overt haemorrhagic cystitis complicating bone marrow transplantation.

Anskar Y. H. Leung; Raymond H. Mak; A. K. W. Lie; Kwok-Yung Yuen; V. C. C. Cheng; Rhs Liang; Yl Kwong

Haemorrhagic cystitis (HC) is an important complication after bone marrow transplantation (BMT). Overt HC (grade ⩾2, gross haematuria, clot retention and impairment of renal function), clinically more important than mild and occult HC (grade 1, microscopic haematuria), leads to substantial morbidity and occasional mortality. We retrospectively analyzed 32 cases of clinically overt HC from a series of 236 BMT patients. Significant risk factors included the use of busulphan during conditioning, allogeneic BMT and acute GVHD. Logistic regression showed GVHD to be the most important risk factor. According to the time of engraftment, HC could be divided into pre- and post-engraftment subtypes. Pre-engraftment HC was brief, not more severe than grade 2, and subsided with supportive treatment. In contrast, post-engraftment HC was protracted, often of grade ⩾3, associated with severe GVHD, and required surgical intervention in many cases. Polyoma BK viruria, but not adenoviruria, could be demonstrated in both types of HC. The increased severity and association with GVHD of post-engraftment HC suggested that attack of urothelium by immunocompetent cells, possibly directed against BK viral antigens, might play a pathogenetic role.Bone Marrow Transplantation (2002) 29, 509–513. doi:10.1038/sj.bmt.1703415


Clinical Infectious Diseases | 2005

Fatal Interaction between Clarithromycin and Colchicine in Patients with Renal Insufficiency: A Retrospective Study

Ivan Fan-Ngai Hung; Alan K. L. Wu; V. C. C. Cheng; Bone Siu-Fai Tang; K.W.K. To; Chung-Kwong Yeung; Pcy Woo; S. K. P. Lau; B. M. Y. Cheung; Kwok-Yung Yuen

BACKGROUNDnClarithromycin is frequently used to treat community-acquired pneumonia in elderly persons. Like erythromycin, it may interact with other drugs by interfering with metabolism by cytochrome P450 enzymes and with the P-glycoprotein transporter system. Colchicine, used for treatment of acute gout and for prophylaxis, may cause bone marrow toxicity. It is metabolized by CYP3A4 and is transported by P-glycoprotein. Initial case reports suggested potentially fatal interactions between clarithromycin and colchicine.nnnMETHODSnA retrospective study was conducted with 116 patients who were prescribed clarithromycin and colchicine during the same clinical admission. Case-control comparisons were made between patients who received concomitant therapy with the 2 drugs and patients who received sequential therapy. We assessed the clinical presentations and outcomes of the 2 patient groups and analyzed the risk factors associated with fatal outcomes.nnnRESULTSnNine (10.2%) of the 88 patients who received the 2 drugs concomitantly died. Only 1 (3.6%) of the 28 patients who received the drugs sequentially died. Multivariate analysis of the 88 patients who received concomitant therapy showed that longer overlapped therapy (relative risk [RR], 2.16; 95% confidence interval [CI], 1.41-3.31; P< or =.01), the presence of baseline renal impairment (RR, 9.1; 95% CI, 1.75-47.06; P<.001), and the development of pancytopenia (RR, 23.4; 95% CI, 4.48-122.7; P<.001) were independently associated with death.nnnCONCLUSIONSnClarithromycin increases the risk of fatal colchicine toxicity, especially for patients with renal insufficiency. Since there are other drugs for treatment of pneumonia and gout, these 2 drugs should not be coprescribed, because of the risk of fatality.


Journal of Clinical Virology | 2009

Differential susceptibility of different cell lines to swine-origin influenza A H1N1, seasonal human influenza A H1N1, and avian influenza A H5N1 viruses

Iris Ws Li; Kh Chan; K.W.K. To; S. S. Y. Wong; Pak-Leung Ho; S. K. P. Lau; Patrick C. Y. Woo; Hoi-Wah Tsoi; Jasper Fuk-Woo Chan; V. C. C. Cheng; Bo-Jian Zheng; Honglin Chen; Kwok-Yung Yuen

BACKGROUNDnThe novel swine-origin influenza A H1N1 virus (S-OIV) causes the current pandemic. Its tissue tropism and replication in different cell lines are not well understood.nnnOBJECTIVEnCompare the growth characteristics of cell lines infected by S-OIV, seasonal influenza A H1N1 (sH1N1) and avian influenza A H5N1 (H5N1) viruses and the effect of temperature on viral replication.nnnSTUDY DESIGNnCytopathic effect (CPE), antigen expression by immunofluorescence (IF) and viral load profile by quantitative RT-PCR in 17 cell lines infected by S-OIV, sH1N1 and H5N1 were examined. Comparison of their replication efficiency in chick embryo was performed. The effect of temperature on viral replication in Madin-Darby canine kidney (MDCK) cells was determined by TCID(50) at 33 degrees C, 37 degrees C and 39 degrees C for 5 consecutive days.nnnRESULTSnS-OIV replicated in cell lines derived from different tissues or organs and host species with comparable viral load to sH1N1. Among 13 human cell lines tested, Caco-2 has the highest viral load for S-OIV. S-OIV showed a low viral load with no CPE or antigen expression in pig kidney cell PK-15, H5N1 demonstrated the most diverse cell tropism by CPE and antigen expression, and the highest viral replication efficiency in both cell lines and allantoic fluid. All three viruses demonstrated best growth at 37 degrees C in MDCK cells.nnnCONCLUSIONnCell line growth characteristics of S-OIV, sH1N1 and H5N1 appear to correlate clinically and pathologically with involved anatomical sites and severity. Low replication of S-OIV in PK-15 suggests that this virus is more adapted to human than swine.

Collaboration


Dive into the V. C. C. Cheng's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Kh Chan

University of Hong Kong

View shared research outputs
Top Co-Authors

Avatar

Pcy Woo

University of Hong Kong

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Pak-Leung Ho

University of Hong Kong

View shared research outputs
Top Co-Authors

Avatar

S. K. P. Lau

University of Hong Kong

View shared research outputs
Top Co-Authors

Avatar

Chung-Ming Chu

United Christian Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ayy Wu

University of Hong Kong

View shared research outputs
Top Co-Authors

Avatar

K. S. Chan

United Christian Hospital

View shared research outputs
Researchain Logo
Decentralizing Knowledge